Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis

References

• KvienTKEpidemiology and burden of illness of rheumatoid arthritisPharmacoeconomics2004222 Suppl 111215157000
   PubMed Web of Science ®Google Scholar
• HelmickCGFelsonDTLawrenceRCEstimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part IArthritis Rheum2008581152518163481
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis201473349250924161836
   PubMed Web of Science ®Google Scholar
• SalliotCVan Der HeijdeDLong term safety of methotrexate monotherapy in rheumatoid arthritis patients: a systematic literature researchAnn Rheum Dis20096871100110419060002
   PubMed Web of Science ®Google Scholar
• de ThurahANorgaardMHarderIStengaard-PedersenKCompliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine: a prospective cohort studyRheumatol Int201030111441144819823840
   PubMed Web of Science ®Google Scholar
• ListingJStrangfeldARauRClinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics registerArthritis Res Ther20068R6616600016
   PubMed Web of Science ®Google Scholar
• AsklingJForedCMBrandtLTime-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonistsAnn Rheum Dis200766101339134417261532
   PubMed Web of Science ®Google Scholar
• HeibergMSKoldingsnesWMikkelsenKThe comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter studyArthritis Rheum200859223424018240258
   PubMed Web of Science ®Google Scholar
• LeeSJChangHYaziciYGreenbergJDKremerJMKavanaughAUtilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort studyJ Rheumatol20093681611161719369454
   PubMed Web of Science ®Google Scholar
• MarietteXGottenbergJERavaudPCombeBRegistries in rheumatoid arthritis and autoimmune diseases: data from the French registriesRheumatology201150122222921148156
   PubMed Web of Science ®Google Scholar
• SolimanMMAshcroftDMWatsonKDLuntMSymmonsDPHyrichKLImpact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterAnn Rheum Dis201170458358921330639
   PubMed Web of Science ®Google Scholar
• PappasDAReedGWSaundersKCharacteristics associated with biologic monotherapy use in biologic-naive patients with rheumatoid arthritis in a US registry populationRheumatol Ther201528596
   PubMed Web of Science ®Google Scholar
• YaziciYShiNJohnAUtilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapyBull NYU Hosp Jt Dis2008662778518537774
   PubMedGoogle Scholar
• Cimzia® (Certolizumab pegol) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdfAccessed November 8, 2013
   Google Scholar
• Enbrel® (Etanercept) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdfAccessed November 8, 2013
   Google Scholar
• Humira® (Adalimumab) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdfAccessed November 8, 2013
   Google Scholar
• Roactemra® (Tocilizumab) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdfAccessed November 8, 2013
   Google Scholar
• Remicade® (Infliximab) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdfAccessed November 8, 2013
   Google Scholar
• Simponi® (Golimumab) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000992/WC500052368.pdfAccessed November 8, 2013
   Google Scholar
• MabThera® (Rituximab) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdfAccessed November 8, 2013
   Google Scholar
• Kineret® (Anakinra) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000363/WC500042310.pdfAccessed November 8, 2013
   Google Scholar
• Orencia® (Abatacept) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000701/WC500048935.pdfAccessed November 8, 2013
   Google Scholar
• GabayCEmeryPvan VollenhovenRADACTA Study InvestigatorsTocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trialLancet201338198771541155023515142
   PubMed Web of Science ®Google Scholar
• NixonRMBansbackNBrennanAUsing mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritisStat Med20072661237125416900557
   PubMed Web of Science ®Google Scholar
• DevineEBAlfonso-CristanchoRSullivanSDEffectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approachPharmacotherapy2011311395121182357
   PubMed Web of Science ®Google Scholar
• SuttonAJAbramsKRBayesian methods in meta-analysis and evidence synthesisStat Methods Med Res200110427730311491414
   PubMed Web of Science ®Google Scholar
• JonasDEWilkinsTMBangdiwalaSFindings of Bayesian Mixed Treatment Comparison Meta-Analyses: Comparison and Exploration Using Real-World Trial Data and Simulation [Internet]Rockville, MDAgency for Healthcare Research and Quality (US)2013
   Google Scholar
• SalliotCFinckhAKatchamartWIndirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysisAnn Rheum Dis201170326627121097801
   PubMed Web of Science ®Google Scholar
• SchmitzSAdamsRWalshCDBarryMFitzGeraldOA mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approachAnn Rheum Dis201271222523021960560
   PubMed Web of Science ®Google Scholar
• AaltonenKJVirkkiLMMalmivaaraAKonttinenYTNordströmDCBlomMSystematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritisPLoS One201271e3027522272322
   PubMed Web of Science ®Google Scholar
• HochbergMCBerrySBroglioKMixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritisCurr Med Res Opin201329101213122223745516
   PubMed Web of Science ®Google Scholar
• BergmanGJHochbergMCBoersMWintfeldNKielhornAJansenJPIndirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugsSemin Arthritis Rheum201039642544120223500
   PubMed Web of Science ®Google Scholar
• TurkstraENgSKScuffhamPAA mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritisCurr Med Res Opin201127101885189721848493
   PubMed Web of Science ®Google Scholar
• Gallego-GalisteoMVilla-RubioAAlegre-del ReyEMárquez-FernándezERamos-BáezJJIndirect comparison of biological treatments in refractory rheumatoid arthritisJ Clin Pharm Ther201237330130721831256
   PubMed Web of Science ®Google Scholar
• FelsonDTAndersonJJBoersMAmerican College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritisArthritis Rheum19953867277357779114
   PubMed Web of Science ®Google Scholar
• OrmeMEMacgilchristKSMitchellSSpurdenDBirdASystematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70Biologics2012642946423269860
   PubMedGoogle Scholar
• LunnDJBestNThomasAWakefieldJSpiegelhalterDBayesian analysis of population PK/PD models: general concepts and softwareJ Pharmacokinet Pharmacodyn200229327130712449499
   PubMed Web of Science ®Google Scholar
• SpiegelhalterDThomasABestNLunnDWin-BUGS User Manual: Version 1.4Cambridge, MAMRC Biostatistics Unit2003
   Google Scholar
• SpiegelhalterDJAbramsKRMylesJPBayesian Approaches to Clinical Trials and Health-Care Evaluation (Statistics in Practice)Chichester, EnglandJohn Wiley & Sons Ltd2004
   Google Scholar
• CaldwellDAdesAHigginsJSimultaneous comparison of multiple treatments: combining direct and indirect evidenceBr Med J2005331752189790016223826
   PubMed Web of Science ®Google Scholar
• CiprianiAFurukawaTASalantiGComparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysisLancet2009373966574675819185342
   PubMed Web of Science ®Google Scholar
• WeltonNJCaldwellDMAdamopoulosEVedharaKMixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart diseaseAm J Epidemiol200916991158116519258485
   PubMed Web of Science ®Google Scholar
• MorelandLWSchiffMHBaumgartnerSWEtanercept therapy in rheumatoid arthritis. A randomized, controlled trialAnn Intern Med1999130647848610075615
   PubMed Web of Science ®Google Scholar
• BathonJMMartinRWFleischmannRMA comparison of etanercept and methotrexate in patients with early rheumatoid arthritisN Engl J Med2000343221586159311096165
   PubMed Web of Science ®Google Scholar
• van de PutteLBAtkinsCMalaiseMEfficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedAnn Rheum Dis200463550851615082480
   PubMed Web of Science ®Google Scholar
• KlareskogLvan der HeijdeDde JagerJPTEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigatorsTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet2004363941067568115001324
   PubMed Web of Science ®Google Scholar
• BreedveldFCWeismanMHKavanaughAFThe PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis Rheum2006541263716385520
   PubMed Web of Science ®Google Scholar
• MainiRNTaylorPCSzechinskiJCHARISMA Study GroupDouble-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis Rheum20065492817282916947782
   PubMed Web of Science ®Google Scholar
• NishimotoNHashimotoJMiyasakaNStudy of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumabAnn Rheum Dis20076691162116717485422
   PubMed Web of Science ®Google Scholar
• JonesGSebbaAGuJComparison of tocilizumab mono-therapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnn Rheum Dis2010691889619297346
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamamotoKStudy of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapyMod Rheumatol2009191121918979150
   PubMed Web of Science ®Google Scholar
• NamJLRamiroSGaujoux-VialaCEfficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritisAnn Rheum Dis201473351652824399231
   PubMed Web of Science ®Google Scholar
• DiamantopoulosABenucciMCapriSEconomic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in ItalyJ Med Econ201215357658522313326
   PubMedGoogle Scholar
• SoiniEJHallinenTAPuolakkaKVihervaaraVKauppiMJCost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritisJ Med Econ201215234035122168785
   PubMedGoogle Scholar
• JansenJPBuckleyFDejonckheereFOgaleSComparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysisHealth Qual Life Outcomes20141210224988902
   PubMed Web of Science ®Google Scholar
• TanakaTHishitaniYOgataAMonoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsBiologics2014814115324741293
   PubMedGoogle Scholar
• BurmesterGRFeistEKellnerHEffectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)Ann Rheum Dis20117075575921187298
   PubMed Web of Science ®Google Scholar
• SinghJAWellsGAChristensenRAdverse effects of biologics: a network meta-analysis and Cochrane overview (review)Cochrane Database Syst Rev20112CD00879421328309
   PubMed Web of Science ®Google Scholar
• SchoelsMMvan der HeijdeDBreedveldFCBlocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementAnn Rheum Dis201372458358923144446
   PubMed Web of Science ®Google Scholar
• RamiroSGaujoux-VialaCNamJLSafety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritisAnn Rheum Dis201473352953524401994
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Committee to Reevaluate Improvement CriteriaA proposed revision to the ACR20: the hybrid measure of American College of Rheumatology responseArthritis Rheum200757219320217330293
   PubMed Web of Science ®Google Scholar